Using Nucleic Acids to Repair β-Globin Gene Mutations
Year: 2007
Type: dissertation
Abstract: Nucleic acids are an emerging class of therapeutics with the capacity to repair\nboth DNA and RNA mutations in clinically relevant targets. We have used two\napproaches, mobile group II introns and Spliceosome Mediated RNA Trans-splicing\n(SMaRT), to correct β-globin mutations at the DNA and RNA levels respectively. We\nshow that the group II intron inserts site-specifically into its DNA target, even when\nsimilar targets are available. Experiments transitioning this therapeutic into mammalian\ncell systems are then described. We also illustrate how SMaRT RNA repair can be used\nto correct β-globin mutations involved in sickle cell disease and some forms of β-\nthalassemia. We uncovered diverse repair efficiencies when targeting sickle cell versus β-\nthalassemia transcripts in mammalian cells. Possible reasons for this and how it might\ndirect target choice for the SMaRT therapeutic approach are both discussed. The\ntherapeutic molecule in SMaRT, a Pre-Trans-splicing Molecule or PTM, is also delivered\nvia lentivirus to erythrocyte precursors cultured from the peripheral blood of sickle cell\npatients. Preliminary results from these experiments are discussed.
Source: DukeSpace (Duke University)
Author: Kierlin-Duncan, Monique Natasha
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W6987839708
